Merck Ventures Fund

The fund has the mandate to invest in four sector focused areas Healthcare, Life Sciences, Performance Materials and New Businesses, in alignment with the strategic interests of Merck’s business areas, though formally separated by a “Chinese Wall”. The total volume of the corporate venture fund is € 300 million.

Healthcare

The Healthcare fund is the strategic, corporate venture arm of the biopharmaceutical division of Merck. We invest globally in emerging biotechnology companies that develop products and or technologies that have the potential to significantly improve patient outcomes.

Healthcare Team

more about
Jasper Bos
more about
Hakan Goker
more about
Alicia Irurzun-Lafitte
more about
Cheryl Zimberlin
more about
Bram Vanparys
more about
Keno Gutierrez
more about
Jeroen Bakker
more about
Caroline Rufo
more about
Tiziana Rossetti

Along with the Merck Healthcare commitment, our team also manages the Entrepreneur Partnership Program which was established to support the creation of spin-offs from Merck and the Israel Bioincubator, which is focused on pre-seed and seed opportunities coming out of Israel.

The Merck Ventures Israel Bioincubator is a strategic initiative designed to stimulate innovation by bridging the gap between academic research and the biotechnology industry in Israel. Launched in 2011 to offers invest in biomedical innovation in Israel, the Bioincubator both seed financing and access to dedicated laboratory facilities within our Israel based R&D center.

Companies

more about
Artios
more about
Asceneuron
more about
Calypso Biotech
more about
Canbex Therapeutics
more about
F-Star
more about
Forendo Therapeutics
more about
Galecto Biotech
more about
Inthera
more about
iOmx
more about
Metabomed LTD
more about
ObsEva
more about
Prexton Therapeutics
more about
RaNA Therapeutics
more about
Raze Therapeutics
more about
Storm Therapeutics
more about
Synaffix BV
more about
TocopheRx
more about
Vaximm

Life Science

The Life Science Team invests in areas of strategic value to the life science division of Merck.

Life Science Team

more about
Andreas Jurgeit
more about
Clemens Lakner
more about
Nadine Sobotzki

We invest globally in emerging life science companies that develop products, services and or technologies that have the potential to make research and biotech production easier, faster, more successful and enhance customer service. The Life Science team helps driving better solutions for our customers.

Performance Materials

The Performance Materials Fund is the strategic, corporate venture arm of the performance materials division of Merck.

Performance Materials Team

more about
Roel Bulthuis
more about
Laura Braeuninger-Weimer
more about
Sven Harmsen
more about
Christian Patze
more about
Sebastian Schoefer

We invest globally in emerging performance materials companies that develop high-tech chemicals for sophisticated applications. Specialty chemicals, such as liquid crystals for displays, pigments for coating and cosmetics, or high-tech materials for the electronics industry. The Performance Materials team helps driving better solutions for our customers.

Companies

New Businesses

The New Businesses Fund is the strategic, corporate venture arm of Merck.

New Businesses Team

more about
Edward Kliphuis
more about
Alexander Hoffmann
more about
Tony (Cheng-Fu) Chang

We invest globally in companies that pursue interdisciplinary approaches and have new ideas to provide the Merck Group with opportunities that go beyond its existing businesses. The New Businesses team aims to commercialize innovative ideas into possible future markets.

Companies

more about
Akili
more about
Medisafe